Charles C. Wykoff, MD, PhD

Associate Professor of Clinical Ophthalmology, Academic Institute
Associate Clinical Member, Research Institute
Houston Methodist
Weill Cornell Medical College


Charles Wykoff, MD, PhD, graduated Phi Beta Kappa from MIT, received his PhD from Oxford University in England while on a Marshall Scholarship, and his MD from Harvard Medical School. As a medical student he co-authored the book Fighting Global Blindness. While pursuing vitreoretinal training at Bascom Palmer Eye Institute he was awarded a Heed Fellowship, the Ronald G. Michels Fellowship Award, and served as Chief Resident/Co-Director of Ocular Trauma.

Dr. Wykoff has extensive expertise in clinical trial design and coordination. His research interests pertain to angiogenesis and retinal vascular diseases including age-related macular degeneration, diabetic retinopathy, and venous occlusive diseases, as well as vitreoretinal surgery topics such as retinal detachment and macular surgery. Dr. Wykoff has written and published over 120 peer-reviewed scientific manuscripts, book chapters, national meeting presentations and abstracts. Dr. Wykoff is Director of the Retina Consultants of Houston and Houston Methodist Hospital joint Argus II retinal prosthetic program – the only Gulf Coast site approved for surgical implantation of this unique technology for patients blind from retinitis pigmentosa. Dr. Wykoff is Co-Director of the Greater Houston Retina Research Foundation, was awarded the American Academy of Ophthalmology Achievement Award in 2015 and is an elected member of the Retina Society and the Macula Society. He also serves as the Academic Program Director for the Vit-buckle Society Annual Meeting, and is a member of the AAO, ARVO, ASRS and FACS.

Areas Of Expertise

Retina Diabetic retinopathy Macular degeneration Vitreoretinal surgery
Education & Training

Internship, Harvard University
MD, Harvard University
Clinical Fellowship, Bascom Palmer Eye Inst & Hosp
Residency, Bascom Palmer Eye Inst & Hosp

Loss to Follow-Up Among Patients With Proliferative Diabetic Retinopathy in Clinical Practice
Suresh, R, Yu, HJ, Thoveson, A, Swisher, J, Apolinario, M, Zhou, B, Shah, AR, Fish, RH & Wykoff, CC 2020, American Journal of Ophthalmology, vol. 215, pp. 66-71.

Fan, W, Uji, A, Wang, K, Falavarjani, KG, Wykoff, CC, Brown, DM, Van Hemert, J, Sagong, M, Sadda, SR & Ip, M 2020, Retina (Philadelphia, Pa.), vol. 40, no. 6, pp. 1029-1037.

Natural History of Geographic Atrophy Secondary to Age-Related Macular Degeneration: Results from the Prospective Proxima A and B Clinical Trials
Holekamp, N, Wykoff, CC, Schmitz-Valckenberg, S, Monés, J, Souied, EH, Lin, H, Rabena, MD, Cantrell, RA, Henry, EC, Tang, F, Swaminathan, B, Martin, J, Ferrara, D & Staurenghi, G 2020, Ophthalmology, vol. 127, no. 6, pp. 769-783.

New Frontiers in Retina: Highlights of the 2020 angiogenesis, exudation and degeneration symposium
Puliafito, CA & Wykoff, CC 2020, International Journal of Retina and Vitreous, vol. 6, no. 1, 18.

Assessment of the DRCR Retina Network Approach to Management with Initial Observation for Eyes with Center-Involved Diabetic Macular Edema and Good Visual Acuity: A Secondary Analysis of a Randomized Clinical Trial
Glassman, AR, Baker, CW, Beaulieu, WT, Bressler, NM, Punjabi, OS, Stockdale, CR, Wykoff, CC, Jampol, LM & Sun, JK 2020, JAMA ophthalmology, vol. 138, no. 4, pp. 341-349.

Relationship between duration and extent of oedema and visual acuity outcome with ranibizumab in diabetic macular oedema: A post hoc analysis of Protocol I data
Sadda, SR, Campbell, J, Dugel, PU, Holekamp, NM, Kiss, S, Loewenstein, A, Augustin, AJ, Shih, V, Xu, X, Wykoff, CC & Whitcup, SM 2020, Eye (Basingstoke), vol. 34, no. 3, pp. 480-490.

Major, JC, Lampen, SIR, Wykoff, CC, Ou, WC, Brown, DM, Wong, TP & Shah, AR 2020, Retina (Philadelphia, Pa.), vol. 40, no. 3, pp. 552-556.

Complement C3 Inhibitor Pegcetacoplan for Geographic Atrophy Secondary to Age-Related Macular Degeneration: A Randomized Phase 2 Trial
Liao, DS, Grossi, FV, El Mehdi, D, Gerber, MR, Brown, DM, Heier, JS, Wykoff, CC, Singerman, LJ, Abraham, P, Grassmann, F, Nuernberg, P, Weber, BHF, Deschatelets, P, Kim, RY, Chung, CY, Ribeiro, RM, Hamdani, M, Rosenfeld, PJ, Boyer, DS, Slakter, JS & Francois, CG 2020, Ophthalmology, vol. 127, no. 2, pp. 186-195.

Intravitreal Combined Aflibercept + Anti–Platelet-Derived Growth Factor Receptor ß for Neovascular Age-Related Macular Degeneration: Results of the Phase 2 CAPELLA Trial
Heier, JS, Wykoff, CC, Waheed, NK, Kitchens, JW, Patel, SS, Vitti, R, Perlee, L, Chu, KW, Leal, S, Asmus, F, Son, V, Schmelter, T & Brown, DM 2020, Ophthalmology, vol. 127, no. 2, pp. 211-220.

Noncompliance in Prospective Retina Clinical Trials: Analysis of Factors Predicting Loss to Follow-up
Zhou, B, Mitchell, TC, Rusakevich, AM, Brown, DM & Wykoff, CC 2020, American Journal of Ophthalmology, vol. 210, pp. 86-96.

Long-term outcomes of treat-and-extend ranibizumab with and without navigated laser for diabetic macular oedema: TREX-DME 3-year results
Payne, JF, Wykoff, CC, Clark, WL, Bruce, BB, Boyer, DS & Brown, DM 2020, British Journal of Ophthalmology.

Management and Outcomes for Neovascular Age-Related Macular Degeneration: Analysis of United States Electronic Health Records
Kiss, S, Campbell, J, Almony, A, Shih, V, Serbin, M, LaPrise, A & Wykoff, CC 2020, Ophthalmology.

Efficacy and Safety of Abicipar in Neovascular Age-Related Macular Degeneration: 52-Week Results of Phase 3 Randomized Controlled Study
Kunimoto, D, Yoon, YH, Wykoff, CC, Chang, A, Khurana, RN, Maturi, RK, Agostini, H, Souied, E, Chow, DR, Lotery, AJ, Ohji, M, Bandello, F, Belfort, R, Li, XY, Jiao, J, Le, G, Schmidt, W & Hashad, Y 2020, Ophthalmology.

Visual Acuity Variability: Comparing Discrepancies between Snellen and ETDRS Measurements among Subjects Entering Prospective Trials
Yu, HJ, Kaiser, PK, Zamora, D, Bocanegra, M, Cone, C, Brown, DM, Sadda, SVR & Wykoff, CC 2020, Ophthalmology Retina.

Intravitreal Aflibercept for Retinal Nonperfusion in Proliferative Diabetic Retinopathy: Outcomes from the Randomized RECOVERY Trial
Intravitreal Aflibercept for Retinal Nonperfusion in Proliferative Diabetic Retinopathy Study Group 2019, Ophthalmology Retina, vol. 3, no. 12, pp. 1076-1086.

Thresholds for Initiating Treatment of Eyes with Diabetic Macular Edema and Good Vision: Consideration of DRCR.Net Protocol V Results
Wykoff, CC 2019, Ophthalmology Retina, vol. 3, no. 11, pp. 917-919.

Progression characteristics of ellipsoid zone loss in macular telangiectasia type 2
The MacTel Study Group 2019, Acta Ophthalmologica, vol. 97, no. 7, pp. e998-e1005.

Distribution of Nonperfusion and Neovascularization on Ultrawide-Field Fluorescein Angiography in Proliferative Diabetic Retinopathy (RECOVERY Study): Report 1
Fan, W, Nittala, MG, Velaga, SB, Hirano, T, Wykoff, CC, Ip, M, Lampen, SIR, van Hemert, J, Fleming, A, Verhoek, M & Sadda, SVR 2019, American Journal of Ophthalmology, vol. 206, pp. 154-160.

Classification of Regions of Nonperfusion on Ultra-widefield Fluorescein Angiography in Patients with Diabetic Macular Edema
Fang, M, Fan, W, Shi, Y, Ip, MS, Wykoff, CC, Wang, K, Falavarjani, KG, Brown, DM, van Hemert, J & Sadda, SVR 2019, American Journal of Ophthalmology, vol. 206, pp. 74-81.

Office-based intravitreal injection of expansile gas for management of macular hole in previously vitrectomized eyes
Apolinario, MA, Lampen, SIR, Wong, TP, Henry, CR & Wykoff, CC 2019, American Journal of Ophthalmology Case Reports, vol. 15, 100492.

Live Chat Available